Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.810 +0.080 (+2.93%)

Delayed Quote Updated: 11:56 AM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

The Future of Healthcare: 10 Predictions For The Next Decade

March 27, 2025

The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we...

Via MarketMinute

Topics Artificial Intelligence

Editas Medicine Announces Chief Financial Officer Transition

March 20, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential ↗

March 05, 2025

The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027.

Via Stocktwits

Peering Into Editas Medicine's Recent Short Interest ↗

February 25, 2025

Via Benzinga

12 Analysts Have This To Say About Editas Medicine ↗

December 11, 2024

Via Benzinga

Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts ↗

October 23, 2024

Via Benzinga

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

March 05, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Earnings Scheduled For March 5, 2025 ↗

March 05, 2025

Via Benzinga

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

February 24, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

What's going on in today's session ↗

February 20, 2025

Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Top movers in Thursday's session ↗

February 20, 2025

Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Stay updated with the stocks that are on the move in today's pre-market session. ↗

February 20, 2025

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

Top movers analysis one hour before the close of the markets on 2025-02-19: top gainers and losers in today's session. ↗

February 19, 2025

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.

Via Chartmill

Here are the top movers in Wednesday's session. ↗

February 19, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

January 13, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 06, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution ↗

December 17, 2024

Editas Medicine pivots to in vivo gene editing, extends cash runway to 2027, but faces investor caution amid unclear proof-of-concept timelines.

Via Benzinga

Walmart To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Friday ↗

December 13, 2024

Via Benzinga

This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

December 13, 2024

Via Benzinga

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 ↗

December 13, 2024

Editas Medicine pivots to in vivo gene editing, extends cash runway to Q2 2027, and reduces its workforce by 65%. The company reports breakthroughs in HSC and liver editing.

Via Benzinga

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

December 12, 2024

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

December 09, 2024

From Editas Medicine, Inc.

Via GlobeNewswire

Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30 ↗

November 30, 2024

Via Talk Markets

Topics Stocks / Equities

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts ↗

November 25, 2024

Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13.

Via Benzinga

Editas Medicine to Participate in Upcoming Investor Conferences

November 06, 2024

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

November 04, 2024

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

October 22, 2024

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

October 21, 2024

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

October 18, 2024

Webinar to be held on Tuesday, October 22, at 8:00 a.m. ET

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

October 03, 2024

Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities

From Editas Medicine, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.